Influenza, Human: all 2,264 studies
Page 20 of 23. Open to participants first (173), then studies with results posted, then the rest; newest registration first within each.
- Vaccination Against Influenza H1N1 in Rheumatic DiseasesStatus unknownNCT01006681Phase 2
- Comparison of Different Methods for Reducing Pain From Influenza Vaccine InjectionsCompletedNCT01006187Phase 3
- A Clinical Trial of Split-virion Influenza A/H1N1 VaccinesCompletedNCT01004653Phase 4
- Immunogenicity and Safety of Influenza Virus Vaccine, AdimFlu-S (A/H1N1), in Adults and EldersCompletedNCT01003145Not applicable
- Cell Immunity Response to Vaccination Against Influenza in Patients With Rheumatoid ArthritisStatus unknownNCT01002716Phase 4
- Influenza Vaccination in Patients With SclerodermaStatus unknownNCT01002508Phase 4
- Rapid Evaluation of Pandemic H1N1 Influenza Vaccine in Adults With HIVCompletedNCT01002040Phase 4
- Rapid Evaluation of Pandemic H1N1 Influenza Vaccine in Aboriginal Children and AdultsCompletedNCT01001026Phase 4
- Rapid Evaluation of Pandemic H1N1 Influenza Vaccines in Young ChildrenCompletedNCT01000831Phase 4
- Rapid Evaluation of Pandemic H1N1 Influenza Vaccine in Adults Receiving Seasonal Influenza VaccineCompletedNCT01000584Phase 4
- Response to Influenza Virus Vaccination in Patients Immunocompromised Due to ChemotherapyCompletedNCT01000246Not applicable
- Single-blind, Dose-ranging Study of Novel Swine Influenza Virus Vaccine in Japanese Pediatric SubjectsCompletedNCT01000207Phase 2/3
- Study Measuring the Safety, Immunogenicity and Lot Consistency of Cell Derived Influenza VaccineCompletedNCT00999206Phase 3
- Surveillance of Influenza Virus Shedding and Immunologic Response in Immunocompromised Children and Young AdultsCompletedNCT00998803
- Immunogenicity of Novel H1N1 Vaccination Among HIV-Infected Compared to HIV-Uninfected PersonsCompletedNCT00996970
- Post-Authorization Safety Study of GSK Biologicals' Pandemic Influenza Vaccine (H1N1) in the United KingdomCompletedNCT00996853
- Single-blind, Dose-ranging Study of Novel Swine Influenza Virus Vaccine in Japanese Adult SubjectsCompletedNCT00996138Phase 2/3
- VRC 309: A Multi-Center, Open-Label, Randomized Phase I Study of an Investigational Influenza DNA Vaccine Followed by 2009/2010 Seasonal Influenza Trivalent Inactivated Vaccine (TIV) Compared to Two Injections of TIV in Adults 45-70 YearsCompletedNCT00995982Phase 1
- A Study to Assess the Safety and Efficacy of a New Influenza Candidate Vaccine MVA-NP+M1 In Healthy AdultsCompletedNCT00993083Phase 2
- Immunogenicity, Tolerability and Safety of One or Two Doses of an Adjuvanted Swine-origin A H1N1 Influenza Vaccine in Healthy Subjects 18 or More Years of Age Both Vaccinated and Not Yet Vaccinated Against Seasonal Influenza 2009/10CompletedNCT00992212Phase 2
- Crossover Study to Investigate the Safety, Tolerability, and Pharmacokinetics of Repeat Dose Zanamivir/Placebo Via Devices Administered Twice Daily for 5 DaysCompletedNCT00989404Phase 1
- Clinical Trial to Evaluate the Immunogenicity and Safety of the Vaccine Against Influenza A/H1N1WithdrawnNCT00989274Phase 2
- Safety Study of Seasonal Influenza Vaccine by Jet InjectionCompletedNCT00987350Phase 4
- The Influence of Fortified Pomegranate Juice (Punica Granatum) on Seasonal Influenza and Swine Flu PatientsStatus unknownNCT00987012Not applicable
- Antiviral Therapy for Influenza A H1N1CompletedNCT00985582
- A Pilot Study for Collection of Anti-Influenza A Immune PlasmaCompletedNCT00984451
- Direct and Indirect Benefits of Influenza Vaccination in Schools and HouseholdsCompletedNCT00981513Phase 4
- Swine Flu (Novel Influenza A H1N1) Vaccine StudyCompletedNCT00980850Phase 2
- Immunogenicity, Safety and Optimal Dose Finding Study of Recombinant Influenza H5N1 Vaccine in Healthy Young AdultsCompletedNCT00980447Phase 2
- Long Term Influenza Prophylaxis With Inhaled Zanamivir or Oral OseltamivirCompletedNCT00980109Phase 4
- A Clinical Trial Comparing Oseltamivir With Placebo And Zanamivir With Control As First Line Treatment For Human Swine Influenza InfectionTerminatedNCT00979667Phase 3
- Oral Triple Combination Antiviral Drug Therapy for Treatment of Influenza A in Immunocompromised SubjectsCompletedNCT00979251Phase 2
- A/H1N1 Immunogenicity and Safety in Infants, Children and AdolescentsCompletedNCT00976469Phase 1/2
- Novel Influenza A/H1N1 Split- Virion Vaccine in Healthy Population Aged 3 Years and OlderCompletedNCT00975572Phase 2
- VRC 308: An Open-Label Phase I Study of the Safety and Immunogenicity of an Investigational H1 DNA Influenza Vaccine, VRC-FLUDNA057-00-VP, in Healthy Adults 18-70 Years OldCompletedNCT00973895Phase 1
- Immunogenicity, Safety and Tolerability of Two Doses of Adjuvanted and Non-adjuvanted Swine Origin A/H1N1 Monovalent Influenza Vaccine (Egg-Derived) in Healthy Subjects From 6 Months to 17 Years of AgeCompletedNCT00971542Phase 3
- Immunogenicity, Safety and Tolerability of Two Doses of Adjuvanted and Non-adjuvanted Swine Origin A/H1N1 Monovalent Influenza Vaccine in Healthy Subjects From 6 Months to 17 Years of AgeCompletedNCT00971100Phase 3
- Immunogenicity, Safety and Tolerability of Two Doses of Adjuvanted and Non-adjuvanted Swine Origin A/H1N1 Monovalent Influenza Vaccine in Healthy Subjects 18 or More Years of AgeCompletedNCT00970177Phase 3
- Rapid Evaluation of Seasonal Influenza VaccineWithdrawnNCT00966342Phase 1
- CSL H1N1 Influenza Vaccine Administered at Different Dose Levels With and Without AS03 Adjuvant in Healthy Adult and Elderly PopulationsWithdrawnNCT00964951Phase 2
- Reactogenicity, Immunogenicity of Trivalent Influenza Vaccine With Recombinant Interferon Alpha Among Chronic Lymphocytic LeukemiaWithdrawnNCT00962715Phase 1/2
- Evaluation of a School-based Influenza Vaccination ProgramCompletedNCT00961337Phase 4
- A/H1N1 Immunogenicity and Safety in AdultsCompletedNCT00959465Phase 1/2
- Safety and Immunogenicity of Influenza Vaccine (Surface Antigen, Inactivated) [Ph.Eur], Formulation 2009-2010, When Administered to Non-Elderly Adult and Elderly SubjectsCompletedNCT00956449Phase 2
- A Study of Inactivated Swine-Origin A/H1N1 Influenza Vaccines in Healthy European Subjects Aged 3 to 17 YearsCompletedNCT00956202Phase 2
- A Clinical Trial With Influenza A/H1N1 VaccinesCompletedNCT00956111Phase 4
- A Study of Swine-origin A/H1N1 Influenza Vaccines in Healthy Europeans Children Aged 6 to 35 MonthsCompletedNCT00956046Phase 2
- A Study of Swine-origin A/H1N1 Influenza Vaccines in Healthy European Adults and the ElderlyCompletedNCT00954798Phase 2
- Observational Study to Assess Safety of H1N1 Pandemic Influenza VaccineCompletedNCT00950456
- Safety and Efficacy Study of Inhaled PUR003 on a Controlled Influenza Virus Challenge in Healthy Adult SubjectsCompletedNCT00947687Phase 1
- Study of Influenza Vaccine (Split Virion, Inactivated) Northern Hemisphere 2009-2010 FormulationCompletedNCT00946179Phase 2
- Safety and Immunogenicity, Inactivated Split Influenza Vaccine, Using the Strain Composition 2009/2010CompletedNCT00945841Phase 3
- Study of the Influenza Vaccine (Split Virion, Inactivated) Northern Hemisphere 2009-2010 Formulation (Intradermal Route)CompletedNCT00945438Phase 2
- Yearly Strain Variation Study, 2009/2010CompletedNCT00943657Phase 3
- Safety and Immunogenicity of A/H1N1v Vaccines in Healthy AdultsCompletedNCT00943358Phase 1
- A Study to Assess the Safety and Immunogenicity of a New Influenza Vaccine Candidate MVA-NP+M1 in Healthy AdultsCompletedNCT00942071Phase 1
- Safety, Tolerability and Immunogenicity of Fluzone® With and Without JVRS-100 in Elderly SubjectsCompletedNCT00936468Phase 2
- Chinese Medicinal Herbs Treatment on Novel Influenza A (H1N1)Pneumonia: Multi-centre, Prospective, Randomized Controlled StudyStatus unknownNCT00936013Phase 4
- Chinese Medicinal Herbs Treatment on Novel Influenza A (H1N1) : Multi-centre, Prospective, Randomized Controlled StudyCompletedNCT00935194Phase 4
- Direct and Indirect Protection by Influenza Vaccine Given to Children in IndiaCompletedNCT00934245Phase 4
- Safety and Immunogenicity of Live Influenza A Vaccine for Avian Influenza H7N7CompletedNCT00922259Phase 1
- Safety of VAX102 Vaccine Given With Seasonal Flu Vaccine in Healthy AdultsCompletedNCT00921973Phase 1
- Study to Investigate the Immune Response to Two Doses of VAX102 Healthy AdultsCompletedNCT00921206Phase 1
- Safety and Immunogenicity of Surface Antigen, Inactivated, Influenza Vaccine Using the Strain Composition 2009/2010 Recommended in Northern Hemisphere in Non-elderly Adult and in Elderly SubjectsCompletedNCT00918268Phase 2
- Safety and Immunogenicity Study of Intramuscular CCS/C-adjuvanted Influenza Vaccine in ElderlyCompletedNCT00915187Phase 2
- Safety and Immunogenicity of Two Doses, Administered Three Weeks Apart, of Two Monovalent H5N1 Influenza Vaccines Containing 2 Doses of H5N1 Influenza Antigen, in Non-elderly Adult and Elderly SubjectsCompletedNCT00914771Phase 2
- Booster Trial to 07-0019 With A/Anhui/05 With and Without MF59CompletedNCT00912496Phase 1
- A Study of a Live Intranasal Influenza Vaccine in Children With CancerCompletedNCT00906750Phase 1
- Nontypeable H. Influenzae in Healthy AdultsCompletedNCT00905385Phase 1/2
- Trial to Evaluate Safety and Immunogenicity of Trivalent Seasonal Influenza Virus-Like Particle (VLP) Vaccine (Recombinant)CompletedNCT00903552Phase 2
- Safety and Immunogenicity of a Split-Virion Pandemic Influenza A (H5N1) Vaccine in ChildrenCompletedNCT00900991Phase 2
- Safety and Immunogenicity of a Split-Virion Pandemic Influenza A (H5N1) Vaccine in AdolescentsCompletedNCT00900588Phase 2
- Immunogenicity and Safety Study of a Single Prime-Boost Vaccination Schedule With a H5N1 Influenza Vaccine in AdultsCompletedNCT00895544Phase 1/2
- Inactivated Influenza Vaccine Effectiveness in Tropical AfricaCompletedNCT00893906Phase 4
- Immunogenicity and Safety of a Cell-derived Influenza Vaccine in Adults Aged >= 18 and <= 64, Plus RevaccinationCompletedNCT00889889Phase 2
- Safety and Immunogenicity of an Intramuscular A/H5N1 Inactivated, Split Virion Pandemic Influenza Vaccine in ChildrenCompletedNCT00884182Phase 2
- Influenza Vaccine in HIV Infected ChildrenCompletedNCT00883012Phase 4
- Annual Study to Investigate Inactivated Subunit Influenza Vaccine Due to New Virus Strains for the 09/10 SeasonCompletedNCT00881842Phase 3
- Bangladesh Secondary Transmission Handwashing ProtocolCompletedNCT00880659Phase 2
- Hutterite Influenza Prevention StudyCompletedNCT00877396Phase 4
- A Study for Evaluation of GSK Biologicals' Pandemic Influenza VaccineWithdrawnNCT00866580Phase 3
- VRC 307: A Double-Blind, Randomized Phase I Study of the Safety and Immunogenicity of a Prime-Boost Schedule of the Investigational DNA Trivalent Influenza Vaccine, VRC-FLUDNA047-00-VP, Followed by the 2008/2009 Seasonal Influenza Trivalent Inactivat...CompletedNCT00858611Phase 1
- Group Study of the Safety of and Immune Response to a Single Dose of Bird Flu Vaccine (H7N3) in Healthy AdultsCompletedNCT00853255Phase 1
- A Study of a Bivalent Influenza Peptide Conjugate Vaccine in Healthy AdultsCompletedNCT00851266Phase 1
- Study of the Effect of Probiotics on Respiratory Morbidity After Influenza Vaccination of Elderly in Nursing HomesCompletedNCT00849277Phase 4
- Study to Assess the Safety of a New GSK Biologicals' GSK2231395A Candidate VaccineTerminatedNCT00849069Phase 1
- A Dose Ranging Study Comparing Different Combinations of Adjuvanted and Non-adjuvanted Influenza Vaccines in Healthy Children 6 to <36 Months of AgeCompletedNCT00848887Phase 1
- Safety, Tolerability, and Immunogenicity of Different Combinations of Trivalent Influenza Vaccine Varying Influenza Antigen Dose, Adjuvant Dose, and Route of Administration in Healthy Elderly Individuals Ages 65 Years and OlderCompletedNCT00848848Phase 1
- Safety and Immunogenicity of Two Doses of Monovalent Inactivated Influenza Vaccine That is Adjuvanted With MF59C.1 (MF59) and Uses a Surface Antigen From a Potential Pandemic Virus Strain Candidate (H5N1) in Adult and Elderly Subjects Using Four Different Vaccination SchedulesCompletedNCT00848029Phase 3
- Study of the Relative Oral Bioavailability of the Antiflu Medicine Oseltamivir in the Intensive Care UnitWithdrawnNCT00844155Not applicable
- Safety and Immunogenicity of Two Doses of Monovalent Inactivated Influenza Vaccine That is Adjuvanted With MF59C.1 (MF59) and Uses a Surface Antigen From a Potential Pandemic Virus Strain Candidate (H5N1) in Adult and Elderly SubjectsCompletedNCT00841646Phase 2
- Tolerability and Measurability of the Efficacy of Non Pharmaceutical Measures to Prevent Seasonal InfluenzaCompletedNCT00833885Not applicable
- Efficacy and Safety of Combination Therapies With Oseltamivir & Zanamivir or Oseltamivir & Amantadine Versus Oseltamivir Monotherapy in the Treatment of Seasonal Influenza A InfectionTerminatedNCT00830323Phase 2
- Antibody Response to Influenza Vaccine in Patients With SarcoidosisCompletedNCT00828828
- Comparison of Fluid Rapid Influenza and BinaxNOW Influenza A & BSuspendedNCT00828100Phase 3
- Prospective Evaluation of the Fluid Rapid Influenza TestSuspendedNCT00826709Phase 3
- Influenza Vaccination in the Emergency DepartmentCompletedNCT00822627Not applicable
- Vitamin A and Maternal-infant Flu Vaccine ResponseCompletedNCT00817661Not applicable
- Immunogenicity of Adjuvanted or Non-adjuvanted H5N1 Booster Vaccine in Adults Primed to A/VN/1194/04CompletedNCT00814385Phase 1/2
- Safety and Immunogenicity of Influenza H9 Vaccine in HumansCompletedNCT00814229Phase 1